Xcout Intel
BenevolentAI
BenevolentAI provides an artificial intelligence platform and life science intelligence tools designed to assist scientists and pharmaceutical executives in drug discovery and research and development decision-making. The company leverages proprietary technology and machine learning to analyze biological data and support complex R&D processes.
Subscribe to see BenevolentAI’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BenevolentAI at a glance
BenevolentAI is a biotech company headquartered in United Kingdom, founded in 2015. It has raised at least $121.2M across the 2 funding rounds on record. Its most recent funding round raised $6.2M in August 2022. Xcout tracks 1 named person at BenevolentAI, including Joanna Shields (Director).
BenevolentAI leadership
- Joanna ShieldsDirector
BenevolentAI funding rounds
At least $121.2M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $6.2M | — | |
| — | $115M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
BenevolentAI competitors
A few of BenevolentAI's closest competitors — see the full list of competitors and alternatives →
BIO-AI, Inc. develops AI-driven world models to simulate human biology across multiple scales. The company builds programmable virtual cells and a general-purpose cell biology simulator to accelerate research and discovery for medicine, biotechnology, and life sciences.
Pathos AI, Inc. is an artificial-intelligence-driven biopharmaceutical company that uses multimodal patient and biological data to discover and develop precision medicines. Its work is focused primarily on oncology and serves patients with serious diseases through pharmaceutical and healthcare partnerships.
Cellarity is a U.S. biotechnology company that uses single-cell biology, computational modeling, and machine learning to discover medicines based on cellular behaviors and disease mechanisms. It serves pharmaceutical and biotechnology development needs, advancing its own therapeutic programs and potentially partnering with other drug developers.
Owkin builds artificial intelligence solutions to automate biopharmaceutical research and development and support clinical research. Its core product, K Pro, is an AI agent that analyzes multimodal patient data to generate insights, inform decision-making, and assist biopharma and healthcare professionals.
Healx is an AI-native pharmaceutical company that uses artificial intelligence and technology to discover and develop new treatments for rare diseases. The company redevelops, combines, and enhances known compounds to build a drug pipeline aimed at delivering effective therapies to patients.
Get BenevolentAI's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BenevolentAI in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access